Three years after Ann Arbor, MI-based Atterocor got started with a lead program for adrenal cancer, the biotech is now ready to launch into its next big stage of development after in-licensing a mid-stage drug from AstraZeneca and raising a whopping $62 million round with plans to roll out a slate of new studies. And the developer will be operating under a new and more easily handled name: Millendo Therapeutics.